Volume 6.45 | Nov 17

Hematopoiesis News 6.45 November 17, 2015
Hematopoiesis News
     In this issue: Publications | Reviews | Science News | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  HN on Twitter
Researchers Identify Emergency Response System for Blood Formation
Scientists determined how the body responds during times of emergency when it needs more blood cells. They report that when tissue damage occurs, in times of excessive bleeding, or during pregnancy, a secondary, emergency blood-formation system is activated in the spleen. [Press release from UT Southwestern Medical Center discussing online prepublication in Nature] Press Release | Abstract
Enter now to win a $500 travel award to attend the Annual American Society for Hematology (ASH) Meeting in Orlando, Florida!
PUBLICATIONS (Ranked by impact factor of the journal)
Targeting Megakaryocytic-Induced Fibrosis in Myeloproliferative Neoplasms by AURKA Inhibition
Researchers showed through pharmacologic and genetic studies that aurora kinase A (AURKA) represents a new therapeutic target in primary myelofibrosis (PMF). Treatment with MLN8237, a selective AURKA inhibitor, promoted polyploidization and differentiation of megakaryocytes with PMF-associated mutations and had potent antifibrotic and antitumor activity in vivo in mouse models of PMF. [Nat Med] Abstract

CLEC-2 in Megakaryocytes Is Critical for Maintenance of Hematopoietic Stem Cells in the Bone Marrow
The authors identified C-type lectin-like receptor-2 (CLEC-2) signaling as a novel molecular mechanism mediating the production of thrombopoietin and other factors for the maintenance of hematopoietic stem cells. [J Exp Med] Abstract

The Role of CD44 in Fetal and Adult Hematopoietic Stem Cell Regulation
Using a CD44-/- mouse model, conserved functional roles of CD44 are revealed throughout development: CD44 is critical in the maintenance of hematopoietic stem and progenitor pools, as well as in hematopoietic stem cell migration. [Haematologica] Abstract | Full Article

Primary Myeloma Interaction and Growth in Coculture with Healthy Donor Hematopoietic Bone Marrow
Researchers established an interactive healthy donor whole bone marrow (BM) based culture system capable of maintaining prolonged survival of primary human primary myeloma cells. This normal BM coculture system was different from using autologous BM that is already affected by the disease. [BMC Cancer] Full Article

SWI/SNF Subunits SMARCA4, SMARCD2 and DPF2 Collaborate in MLL-Rearranged Leukemia Maintenance
Investigators explored the role of SMARCA4 and the two SWI/SNF subunits SMARCD2/BAF60B and DPF2/BAF45D in leukemia. They observed the selective requirement for these proteins for leukemic cell expansion and self-renewal in-vitro as well as in leukemia. [PLoS One] Full Article

LPS-Stimulated Human Bone Marrow Stroma Cells Support Myeloid Cell Development and Progenitor Cell Maintenance
Scientists showed that in addition to enhanced myeloid colony formation from human CD34+ cells, lipopolysaccharide (LPS) stimulation retains overall higher numbers of CD34+ cells in co-culture assays using bone marrow stromal cells, with eightfold more CD34+ cells that underwent up to three divisions as compared to non-stimulated assays. [Ann Hematol] Abstract

Role of Neuropeptide Y in the Bone Marrow Hematopoietic Stem Cell Microenvironment
Researchers demonstrated that neuropeptide Y deficient mice have significantly reduced hematopoietic stem cell numbers and impaired bone marrow regeneration due to apoptotic destruction of sympathetic nervous system fibers and/or endothelial cells. [BMB Rep] Abstract | Download Full Article


Addition of Sorafenib versus Placebo to Standard Therapy in Patients Aged 60 Years or Younger with Newly Diagnosed Acute Myeloid Leukemia (SORAML): A Multicenter, Phase II, Randomized Controlled Trial
The authors investigated the efficacy and tolerability of sorafenib versus placebo in addition to standard chemotherapy in patients with acute myeloid leukemia aged 60 years or younger. [Lancet Oncol] Abstract

Thiotepa-Based High-Dose Therapy for Autologous Stem Cell Transplantation in Lymphoma: A Retrospective Study from the EBMT
Investigators evaluated potential risks and benefits of thiotepa-based preparative regimens compared with BEAM (carmustine, etoposide, cytarabine, melphalan) in auto-stem cell transplantation for diffuse large B-cell lymphoma, follicular lymphoma or Hodgkin lymphoma. [Bone Marrow Transplant] Abstract

New Cell Separation Kits to Isolate 90% Pure CD34+ Cells from Cord Blood. See the data and learn more here!
Unexpected Role of Inflammatory Signaling in Hematopoietic Stem Cell Development: Its Role beyond Inflammation
The authors summarize recent advances in inflammatory signaling with particular focus on how distinct inflammatory signaling regulates hematopoietic stem cell development. [Curr Opin Hematol] Abstract

Visit our reviews page to see a complete list of reviews in the hematopoiesis research field.
AbbVie’s Commitment to Oncology Demonstrated at the 57th American Society of Hematology Annual Meeting with 61 Abstracts Evaluating Medicines in Several Blood Cancers
AbbVie will present data from clinical trials evaluating the company’s oncology portfolio. Data scheduled for presentation include results from studies of venetoclax, an investigational oral B-cell lymphoma-2 (BCL-2) inhibitor, in chronic lymphocytic leukemia (CLL) and other hematological malignancies. [Press release from Abbvie discussing research to be presented at the 57th American Society of Hematology (ASH) Annual Meeting, Orlando] Press Release

From our sponsor: Working with blood? Request your free wallchart on human blood cell frequencies.
ImmunoCellular Therapeutics Enters into Sponsored Research Agreement with University of Texas MD Anderson Cancer Center to Advance Stem-to-T-Cell Program
ImmunoCellular Therapeutics, Ltd. announced it has entered into a sponsored research agreement with Dr. Cassian Yee at the University of Texas MD Anderson Cancer Center. The ultimate goal of this work is to enable a clinical program based on hematopoietic stem cells that are isolated from the patient, engineered in the lab and then returned to the patient to create a population of antigen-specific killer T cells that target and kill the tumor. [ImmunoCellular Therapeutics, Ltd.] Press Release

Infinity Announces Completion Of Target Enrollment in DUO™, A Phase III Study Evaluating Duvelisib in Chronic Lymphocytic Leukemia
Infinity Pharmaceuticals, Inc. announced that it has reached target enrollment of 300 patients in DUO™, a randomized Phase III monotherapy study evaluating the safety and efficacy of duvelisib compared to ofatumumab in patients with relapsed or refractory chronic lymphocytic leukemia. [Infinity Pharmaceuticals, Inc.] Press Release
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW South Central Association of Blood Banks Annual Meeting
June 2-5, 2016
Houston, Texas

NEW The Advanced Immunohematology and Molecular Symposium (AIMS)
July 5-6, 2016
Houston, Texas

Visit our events page to see a complete list of events in the hematopoiesis community.
NEW Team Leader/Professor/Associate Professor – Regenerative Medicine (Ji Nan University)

Principal Scientist – Hematopoietic Products (STEMCELL Technologies Inc.)

Postdoctoral Researcher – Cardiovascular/Hematopoietic Development (Kumamoto University)

Postdoctoral Fellow – Leukemia Research (City of Hope)

Postdoctoral Position – Stem Cells and Leukemia (Florida State University)

PhD Studentships – Cancer Research (Cancer Research UK Manchester Institute)

Assistant or Associate Professor – Cell and Regenerative Biology (University of Wisconsin, Madison)

Postdoctoral Research Fellow – Medicinal Chemistry for Cancer Drug Discovery (University of Michigan)

Research Technician – Stem Cell and Gene Therapy (Fred Hutchinson Cancer Research Center)

Postdoctoral Fellow – iPSC Models of Hematologic Disorders (Icahn School of Medicine at Mount Sinai)

Postdoctoral Fellow – Leukemia, Stem Cells and Development (Josep Carreras Leukemia Research Institute)

Postdoctoral Positions – Cancer and Developmental Biology (North Carolina Central University)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Hematopoiesis News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Hematopoiesis News: Archives | Events | Contact Us